<DOC>
	<DOC>NCT02360774</DOC>
	<brief_summary>The purpose of this study is to investigate the effect of canagliflozin, a medication approved by the FDA for the treatment of type 2 diabetes, on body weight and metabolism in people with type 2 diabetes who are overweight or obese. Canagliflozin lowers glucose levels in the blood by making the kidneys excrete, rather than absorb, glucose. Canagliflozin is also often associated with weight loss. The study population will generally be type 2 diabetics, ages 18-75 years old, who are overweight or obese.</brief_summary>
	<brief_title>Mechanisms of Weight Loss With SGLT2 Inhibition</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>1. Type 2 diabetes 2. BMI 2545 kg/m2 3. Hemoglobin A1C &gt; 6.5% but &lt; 9% 4. Normal renal function (GFR &gt; 60) 5. Age 1875 1. Type 1 diabetes 2. History of recurrent UTI or mycotic genital infections 3. Treatment with insulin or a GLP1 agent 4. Pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Canagliflozin</keyword>
	<keyword>Obesity</keyword>
	<keyword>Weight Loss</keyword>
	<keyword>Body Weight</keyword>
	<keyword>Body Weight Changes</keyword>
	<keyword>Overweight</keyword>
	<keyword>Sodium-glucose transporter subtype 2 inhibitor</keyword>
</DOC>